- Coordinator
- Latvijas Universitate, Latvia
- Runs
- 1 September 2026 to 31 August 2030
- Status
- Running
- EU funding
- €1.6m
- Total cost
- —
- Partners
- 10 organisations in 7 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101299634
What the project is doing
In the project's own words, from its summary on CORDIS.
The MX-WOUND project aims to revolutionize chronic wound care by developing a first-of-its-kind multimodal antibacterial and regenerative platform powered by MXene nanotechnology. Conventional treatments are increasingly ineffective due to multidrug-resistant infections and insufficient regenerative support. MX-WOUND addresses these challenges by uniting targeted antibacterial therapy, photothermal modulation, and regenerative stimulation into a single, clinically translatable solution.
MXenes, a cutting-edge class of 2D transition metal carbides and nitrides, will be polydopamine-coated and conjugated with MRSA-specific antibodies to ensure highly selective bacterial targeting. Combined with near-infrared light-triggered photothermal therapy, this approach enables rapid pathogen eradication with minimal damage to surrounding tissues. In parallel, electrospun and hybrid-spun nanofibrous scaffolds will be engineered to deliver mesenchymal stem cell-derived secretome, promoting angiogenesis, immune modulation, and tissue repair to accelerate wound closure.
MX-WOUND unites leading academic, clinical, and industrial partners from Europe, Ukraine, and the USA in a highly interdisciplinary network. The project follows a rigorous translational pipeline—MXene synthesis and functionalization, scaffold fabrication, in vitro validation, and preclinical in vivo testing—ensuring robustness, scalability, and clinical relevance. Beyond scientific innovation, MX-WOUND will train a new generation of researchers through cross-sectoral secondments, industry placements, and mentoring.
By integrating nanotechnology, precision photothermal therapy, and regenerative medicine, MX-WOUND will deliver a transformative, antibiotic-free therapy for chronic wounds, improve patient outcomes, and help combat the global threat of antimicrobial resistance.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Latvijas Universitate | Riga | Latvia | Coordinator |
| Nanospace Technology Sro | Most | Czechia | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Mb Sensografa | Vilnius | Lithuania | Participant |
| Vilniaus Universitetas | Vilnius | Lithuania | Participant |
| Instytut Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Pan | Wroclaw | Poland | Participant |
| Uniwersytet Im. Adama Mickiewicza Wpoznaniu | Poznan | Poland | Participant |
| Materials Research Center | Kiev | Ukraine | Participant |
| Sumy State University | Sumy | Ukraine | Participant |
| Worcester Polytechnic Institute | Worcester | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI